Skip to content
Back to search results

CHA₂DS₂-VASc Score

Introduced by
Gregory Y. H. Lip, Robby Nieuwlaat, et al.
Year
2010
Type
Atrial fibrillation stroke risk stratification
Family
Clinical scoring
Font size

What does it do?

The CHA₂DS₂-VASc score, developed by Lip, Nieuwlaat, and colleagues in 2010, is a 9-point risk stratification tool for predicting annual stroke and systemic thromboembolism risk in patients with atrial fibrillation.

It is the recommended score by major cardiology guidelines for guiding anticoagulation decisions.

The intuition behind the method

CHA₂DS₂-VASc operationalizes the concept that stroke risk in atrial fibrillation depends on both cardiac factors (heart failure, hypertension) and systemic vascular disease burden. By assigning weighted points to nine risk factors—including age (treated as two separate categories), prior vascular events, and female sex—the score captures the cumulative risk of thromboembolism. Higher scores indicate greater stroke risk and stronger indication for anticoagulation. The score balances sensitivity (avoiding missed strokes) with specificity (avoiding unnecessary anticoagulation in truly low-risk patients).

History

Lip and colleagues developed CHA₂DS₂-VASc in 2010 as an improved version of the simpler CHADS₂ score, incorporating additional risk factors identified in the Euro Heart Survey on AF. The new score provided better discrimination, particularly in women and low-risk populations where CHADS₂ was less accurate. CHA₂DS₂-VASc rapidly gained international adoption and is now the recommended score in major guidelines (ESC 2019, AHA/ACC 2019).

When to use it

CHA₂DS₂-VASc is applied to all patients with atrial fibrillation (paroxysmal, persistent, or permanent) to guide anticoagulation decisions. It is equally applicable in emergency departments for new-onset atrial fibrillation, outpatient cardiology clinics, and primary care. CHA₂DS₂-VASc is less applicable to patients with contraindications to anticoagulation, for whom the score informs risk-benefit discussion.

Limitations and considerations

  • Does not account for reversible causes of atrial fibrillation (e.g., thyrotoxicosis, acute infection) that may affect thromboembolic risk differently
  • Female sex is counted as 1 point without distinction between menopausal and post-menopausal women, potentially overestimating risk in younger women
  • Does not include emerging biomarkers (troponin, natriuretic peptides, biomarkers of atrial fibrillation burden) that may refine risk
  • Age categorization (≥75 vs. 65–74) is somewhat arbitrary and may not capture the continuous relationship between age and stroke risk
  • Does not account for anticoagulation intensity or medication adherence, which influence actual stroke prevention

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Comprehensive assessment of both cardiac and systemic vascular risk factors
  • Superior discrimination compared to simpler scores (e.g., CHADS₂), particularly in low-risk and female populations
  • Strong external validation across diverse populations and geographic regions
  • Incorporates female sex as an independent risk factor (addressing sex disparities in prior scores)
  • Endorsed by major international guidelines (ESC, AHA, ACC), facilitating standardization

Applications

  • Atrial fibrillation anticoagulation decisions: CHA₂DS₂-VASc ≥ 2 in males or ≥ 3 in females warrants oral anticoagulation with warfarin or direct oral anticoagulants
  • Emergency department management of new-onset AF: CHA₂DS₂-VASc guides counseling on stroke risk and anticoagulation initiation decisions
  • Primary care AF monitoring: CHA₂DS₂-VASc recalculated annually (or with new risk factors) to ensure continued appropriateness of anticoagulation
  • AF research and registries: stratification by CHA₂DS₂-VASc enables comparison of stroke outcomes and anticoagulation effectiveness across populations
  • Shared decision-making: CHA₂DS₂-VASc score communicated to patients to explain stroke risk and rationale for anticoagulation recommendations

How it works

How it works

1

A clinician systematically assesses nine variables: congestive heart failure or left ventricular dysfunction, hypertension (on treatment or resting BP > 140/90), age ≥75 years, diabetes mellitus on medication, prior stroke/TIA/systemic thromboembolism (counted as 2 points), vascular disease (prior MI, peripheral artery disease, aortic plaque), age 65–74 years, female sex.

2

Each factor is scored as shown: C=1, H=1, A₂=2 (age ≥75), D=1, S₂=2 (prior stroke), VA=1 (vascular disease), Sc=1 (age 65–74), c=1 (female). Total CHA₂DS₂-VASc ranges from 0 to 9.

3

CHA₂DS₂-VASc 0–1 = low risk, anticoagulation may not be needed. CHA₂DS₂-VASc ≥ 2 in males or ≥ 3 in females = intermediate to high risk, anticoagulation is recommended to prevent stroke.

Common pitfalls

  • Applying CHA₂DS₂-VASc to patients without confirmed atrial fibrillation; the score is specific to AF and does not apply to sinus rhythm.
  • Using CHA₂DS₂-VASc to determine anticoagulation intensity (e.g., warfarin dose or DOAC type); the score guides whether to anticoagulate, not how intensively.
  • Forgetting to double-count prior stroke/TIA (S₂ = 2 points); this common error leads to underestimation of risk.
  • Neglecting to discuss bleeding risk using HAS-BLED or similar scores; CHA₂DS₂-VASc alone is insufficient for anticoagulation decisions if bleeding risk is very high.

Frequently asked questions

My CHA₂DS₂-VASc is 1; do I need anticoagulation?

CHA₂DS₂-VASc = 1 in males is considered low risk and anticoagulation is generally not recommended. However, if CHA₂DS₂-VASc = 1 due to a female patient or age 65-74, reassess more carefully. Some clinicians offer aspirin as a lower-risk alternative, though anticoagulation is preferred if tolerated.

Does my CHA₂DS₂-VASc score change if I'm anticoagulated?

No. CHA₂DS₂-VASc score itself does not change with anticoagulation; it is a static risk assessment at a point in time. However, anticoagulation is the result of the CHA₂DS₂-VASc assessment and effectively reduces stroke risk by ~60–80%.

What is HAS-BLED and how does it relate to CHA₂DS₂-VASc?

HAS-BLED assesses bleeding risk during anticoagulation (hypertension, abnormal renal/liver function, stroke, bleeding history, labile INR, elderly age, drugs/alcohol use). CHA₂DS₂-VASc assesses stroke risk; both should be evaluated to make balanced anticoagulation decisions.

Should I anticoagulate a patient with AF and CHA₂DS₂-VASc ≥ 2 even if they have contraindications?

High CHA₂DS₂-VASc is strong indication for anticoagulation, but absolute contraindications (e.g., active bleeding, severe thrombocytopenia) must be respected. Work to resolve contraindications or consider bridging strategies (e.g., temporary heparin with planned DOAC when contraindication resolves).

Related methods

Sources

  1. Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 137(2), 263-272.

    Open DOI reference
    Copied.
  2. Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J., & Lip, G. Y. (2012). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 138(5), 1093-1100.

    Open DOI reference
    Copied.